Method for prediction of clinical outcome of chemoradiation therapy of squamous cell carcinoma of head and neck. RU patent 2505818.
 Method for assessing radiosensitivity of airway cancer / 2505817What is found is a pre-therapeutic rate of haemopoietic stem cells with immunophenotype CD34+CD45 low among peripheral lymphocytes at the stages T3 or T4 to be compared to its discrimination level of 6.0×10-4. If the value occurs to exceed 6.0×10-4, a high radiosensitivity of the tumour is predicted, while the value of 6.0×10-4 or less enables predicting a low radiosensitivity of the tumour. |
 Cartridge for analyses with magnetic particles / 2505816Cartridge (100) for detecting target components in a liquid sample comprises: a sample chamber (SC); at least two reservoirs (131, 132) filled with magnetic particles(MP, MP'), which are specific for different target components; at least two sensitive zones (121, 122) for detecting magnetic particles and/or target components, wherein magnetic particles (MP, MP') of different reservoirs primarily reach different sensitive zones while migrating into the sample filling the sample chamber under the effect of an activation magnetic field (B). The group of inventions also relates to a method of detecting target components using said cartridge, a device for detecting target components having said cartridge, a magnetic field generator and a sensor unit for detection inside the cartridge and to use of said device for molecular diagnosis, biological analysis of samples or chemical analysis of samples. |
 Antibodies against tenb2 constructed with cysteine, and conjugates, antibody-drug / 2505544There proposed is an antibody specific to TENB2 containing light and heavy chains. Heavy chain contains substitution for free (reaction capable) cysteine A121C that corresponds to A114C (Kabat numbering) or A118C (Eu numbering). Conjugate versions are proposed for prostate cancer treatment containing antibody covalently bound to auristatin, also by means of linker. The following is described: pharmaceutical composition for prostate cancer treatment that uses as active beginning the antibody or its conjugate; product for prostate cancer treatment on the basis of such composition. The invention proposes: method for defining protein TENB2 in the sample - on the basis of antibody as well as analysis for revealing prostate cancer cells at mammal and method for cell proliferation inhibiting on the base of antibody conjugate and auristatin. There described is the method for obtaining antibody conjugate (Ab) and auristatin (D) with expression Ab-(L-D)p, where p is equal from 1 to 4, and L is linker. |
 Method for prediction of pulmonary tuberculosis with multiple drug resistance / 2504787Pulmonary tuberculosis with multiple drug resistance is predicted in the patients newly diagnosed with pulmonary tuberculosis (PT) by determining the pre-therapeutic blood CD45R0+ memory T-cell, CD3+CD4(CD25+hl and CD4+CD25+Foxp3- regulatory T-cell, CD3+CD4+CD25- T-helper counts. Linear classification functions are calculated by equations: d1=-14.0015-0,0626xx1+0,.5181xx2+2.4285xx3+0.2255xx4 and d2=-22.6954-0.1710xx1+0.6689xx2+3.1202xx3+0.3229xx4, wherein x1, x2, x3, x4 are the numbers of the CD45R0+ memory T-cell, CD3+CD4+CD25+hi and CD4+CD25+Foxp3- regulatory T-cell, CD3+CD4+CD25- T-helper subpopulations, respectively. If observing d1<d2, tuberculosis with agent's multiple drug resistance is predicted. |
 Diagnostic technique for urolithiasis / 2504786Original urine sample is divided into two equal samples; particle size histogram is prepared and used to find a percentage of an oligomer form of Tamm-Horsfall protein T&HE(7); the sample histograms are compared. A Tamm-Horsfall protein identification protein is presented by monoclonal antibodies undergoing an immune-affine reaction with Tamm-Horsfall protein. The second sample is used to recover Tamm-Horsfall protein T&HE(28); and both urine samples are used to measure the oligomer form of Tamm-Horsfall protein T&HE(28) in the free condition and in aggregates with oxalate microcrystals (%). The relation of the derived oligomer forms is calculated by formulas: C1=T&HE(28)A/T&HE(7) and C2=T&HE(28)F/T&HE(7). If observing C1>1.5 and any C2, urolithiasis is diagnosed; the relations C1<0.1 and C2<1.81 enable diagnosing the absence of the disease, while the relations C1<1.5 and C2>1.81 make the patient be referred to a risk group of developing urolithiasis. The technique enables distinguishing between those suffering urolithiasis and healthy ones among the persons being tested, and also separating a risk group of developing urolithiasis. |
 Diagnostic technique for breast cancer / 2504785Invention represents a new diagnostic technique based on the detection of protein molecules being antibodies to a specific and sensitive combination of tumour associated glycans with underlying the patient's individual characteristics. The given invention can find application in immunology and medicine for the study and diagnosis of breast cancer. The diagnostic technique for breast cancer involves detecting the human blood antibodies to the following glycans: Manβ1-4GlcNAcβ, Galβ1-4G1cNAcβ1-6(Galβ1-3)GalNAcα, HOCH2(HOCH)4CH2NH2, GlcAβ, Galα, 6-O-Su-GlcNAcβ, GalNAcβ1-3Galβ, 6-O-Su-Galβ1-4(6-O-Su)Glcβ, GlcAβ1-SGa1β, Neu5Acα2-3Gaiβ1-4Glcβ, GlcNAcβ1-3Galβ1-3GalNAcα, Neu5Acα2-3Galβ1-3GalNAcα, Neu5Acα2-3Galβ1-3(Fucα1l-4)GlcNAcβ, Gaiβ1-4GlcNAcβ1-3(GlcNAcβ1-6)Gaiβ1-4GlcNAcβ, Neu5Acα2-6(Galβ1-3)GlcNAcβ1-3Galβ1-4Glcβ with using a microchip with applied glycans; if the blood antibody level turns out to be higher than a threshold value to the above glycans simultaneously, breast cancer is diagnosed. |
 Diagnostic technique for secondary immunodeficient disease in pulmonary tuberculosis / 2504784Prescribing the specific chemotherapy is preceded by the immunological examination of peripheral blood of the patients suffering pulmonary tuberculosis and the determination of cell, humoral and molecular-genetic parameters of the patient's immune status. The peripheral blood CD4+CD25-Foxp3+ regulatory T-cell count more than 2.6%, the peripheral blood CD4+CD25+Foxp3+ regulatory T-cell count more than 5.1%, the peripheral blood CD3+CD4- CD25+ regulatory T-cell count more than 0.2%, the peripheral blood CD4+CD25+Foxp3- regulatory T-cell/activated T-helper count less than 25.5%, the peripheral blood CD3+CD4+CD25- T-helper count less than 35.4%, the peripheral blood γδT-lymphocyte count less than 4.9%, the peripheral blood CD45R0+ memory T-cell count less than 8.9%; 1L-2 less than 22.3 pg/ml, IL-4 more than 40.0 pg/ml, IL-10 more than 25.3 pg/ml, TGFβ more than 1109.0 pg/ml in a combination with the carriage of the allele C and genotype GG T-330G of IL2 gene and the allele A and genotype AA C-592A of IL10 gene, of the allele T and genotype TT C-509T of TGFB gene, and the allele T and genotype TT C-590T of IL4 gene, secondary immunodeficient disease is diagnosed. |
| Diagnostic technique for autoimmune versions of diabetes mellitus / 2504783 Diagnostic technique for the autoimmune versions of diabetes mellitus, with the autoimmune versions of diabetes mellitus being diagnosed by comparing the production of tumour necrosis factor alpha (TNFα) (pcg/ml) in supernatant after lymphocyte culture taken from patient's blood sample in the autoantigen insulin stimulation environment. The test is considered to be positive if the TNFα in the insulin post-stimulation sample increases its value in the no-stimulation environment. |
| Method for evaluating clinical effectiveness in ulcerative colitis / 2504779 Induction standard therapeutic course is followed by determining the blood serum lactoferrin concentration, and if the derived values exceed 874.7±21.6 ng/ml, the absence of a clinical remission of ulcerative colitis is stated. |
| Method for preparing antigen for serum diagnosis of small cattle anaplasmosis / 2503461 Invention refers to veterinary protozoology and concerns a method for preparing an antibody for serum diagnosis of small cattle anaplasmosis. The presented method involves introducing an infective dose of 14·1010 or 16·107 anaplasma/animal on the 15th or 22nd-24th day respectively into a splenectomised animal, carrying out exsanguination, centrifuging blood for 2-3 times at 6000 rpm for an hour with physiological solution at pH 6.8-7.2, preparing the anaplasma residue with blood corpuscles, washing in physiological solution for 2-3 times, performing erythrocytoschisis by 2-3 cycles of freezing and thawing, concentrating for 2-3 times by centrifugation in the same environment and recovering the antigen with titre 1:32-1:64. |
 Method for predicting the character of bacterial keratitis flow / 2245553In lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula: At PC value being below 10.0 one should predict favorable disease flow, and at PC value being above 10.0 - unfavorable flow. |
| Method for determination of anti-lactoferrin activity in microorganisms / 2245923 Method involves growing microorganism culture to be studied in solid nutrient medium followed by preparing microbial suspension and its incubation in the presence of lactoferrin. Control sample is prepared in parallel series. Control and experimental samples are incubated, supernatant is removed from bacterial cells and lactoferrin concentration is determined in supernatant of experimental and control sample by immunoenzyme analysis. Then anti-lactoferrin activity is calculated by difference of concentrations of residual lactoferrin in experimental and control samples. This method provides enhancing the sensitivity and precision in carrying out the quantitative evaluation of anti-lactoferrin activity in broad spectrum of microorganisms that is urgent in diagnosis and prognosis of diseases with bacterial etiology. Invention can be used in determination of persistent indices of microorganisms for assay of their etiological significance in pathological processes. |
| Nutrient medium for accumulation of cell sample for following cytological and/or immunocytochemical analysis / 2246110 Invention relates to nutrient medium used for accumulation of cells for the following cytological and/or immunocytochemical analysis carrying out. Invention relates to medium containing salts NaCl, KCl, anhydrous CaCl2, MgSO4 x 6 H2O, MgCl2 x 6 H2O, Na2HPO4 x 2 H2O, KHPO4, NaHCO3, and also glucose and Henx's solution, 10% albumin solution and polyglucin taken in the ratio 1:1:1. Invention provides enhancing the preservation of cells. |
| Method for predicting lethal result of large-focal myocardial infarction / 2246114 In peripheral blood one should detect the level of CD95(+) and CD16(+) neutrophilic granulocytes and at combination of increased level of CD95(+) neutrophilic granulocytes by 4 times and more and CD16(+) neutrophilic granulocytes by 0.6 times against the norm with ECG signs of myocardial infarction one should predict lethal result of large-focal myocardial infarction. |
 Method for predicting lambliasis and its flow / 2246115One should carry out immunoenzymatic assay to detect diagnostic optic density and that of labeled immune complex in a plot's hole with tested serum measured in conventional units at wave length being 492 nm. One should calculate coefficient of antibodies concentration measured in conventional units by the following formula: CAC = (Odtsh - Odd) x 100, where CAC - coefficient of antibodies concentration, Odtsh - optic density of the hole with tested serum, Odd - diagnostic value of optic density, 100 - coefficient of serumal dilution. By CAC value one should detect the titer of antibodies to Lamblia intestinalis antigens to interpret results of the trial. The method enables to study the dynamics of disease flow. |
 Method for detecting adhesive properties of blood leukocytes / 2246728The present innovation deals with studying and treating diseases of inflammatory, autoimmune and degenerative genesis. One should perform sampling of heparinized blood followed by its sedimentation to obtain blood plasma with leukocytes and centrifuging to isolate the latter which are washed against erythrocytic and serumal admixtures, and, also, it deals with calculating the number of cells in samples out of leukocytic suspension after incubation (B) for 1.5 h at 37 C in holes of plastic microplotting board, out of leukocytic suspension one should additionally prepare two samples, one should be applied to calculate total number of leukocytes before incubation (A), the second sample undergoes incubation at the same mode at addition of autoserum to calculate the number of cells remained after incubation (C). One should state upon adhesive properties of leukocytes by the index of spontaneous adhesion (D), where D=(A-B)/B.100%, and effect for enhanced cellular adhesion under the impact of autoserum should be detected by the value of K=(B-C)/C.100% at K ≥ 30%, where B - C - the number of cells undergone additional adhesion after addition of autoserum. The present innovation widens functional possibilities of the suggested method due to obtaining additional values depicting adhesive properties of blood leukocytes. |
| Method for detecting functional activity of cytokins that suppress t-lymphocytes in neonatals / 2246732 One should carry out reaction of blast-transformation, detect proliferation of T-lymphocytes activated with antibodies to CD3 in the presence of interleukin-7 (ACT IL-7) and in the presence of interleukin-7 and dexametazone (ACT IL-7 D), calculate the index for dexametazone action as the ratio of ACT IL-7 to ACT IL-7 D, moreover, the value of dexametazone action index being above 1.2 indicates increased production of cytokins that suppress T-lymphocytes in neonatals. The method enables to detect functional defect of immune system that characterizes neonatal period. |
| Method for predicting pulmonary hypertension / 2247380 Method involves measuring forced exhalation volume per 1 s (FEV1) in l, full right ventricle evacuation time (RVE) in ms and angiotensin II value (AII) in ng/l. Discriminant relationship is built as D=0.504·RVE+3.038·FEV1 - 2.0·AII. D being less than 83.88, pulmonary hypertension occurrence is predicted within 1 year. D being equal to or greater than 83.88, no pulmonary hypertension is predicted to occur. |
| Method for assay of immune status disorder / 2247381 Method involves determination of heterophilic antibodies in human serum blood by the Paul-Bunnel's method relatively the level of circulating immune complexes, complement-activating properties of heterophilic antibodies by incubation of standardized ram erythrocytes with 0.8% serum for 30 ± 5 min and the following measurement of the erythrocytes lysis degree. The measurement of the effector function coefficient of heterophilic antibodies is carried out by the complement system Keff.f.h.a.-c.s. by the formula: Keff.f.h.a.-c.s. = Y/Tg.a. wherein Y means a lysis degree, %; Tg.a. means a reverse titer of heterophilic antibodies to ram erythrocytes. The damage assay is carried out by comparison of the immune status with the relative level of circulating immune complexes in serum. Method provides detection of preclinic from of immunodeficiency and autoimmune diseases that opens the possibility for their prophylaxis at most early stages of development. Invention can be used for assay of damage in the immune status in human serum blood. |
| Method for predicting ophthalmoherpes / 2247382 Method involves concurrently examining anti-inflammatory IL-4 level in blood serum and lacrimal fluid. The value being within the limits of 60-70 pg/l in blood serum and 5-15 pg/l in lacrimal fluid, disease prognosis is considered to be unfavorable. The IL-4 concentration being within the limits of 90-100 pg/l in blood serum and 20-30 pg/l in lacrimal fluid, disease prognosis is considered to be favorable. |
FIELD: medicine.
SUBSTANCE: immunoenzymometric analysis of blood serum TIMP-1 and TIMP-2 is combined with determining a primary tumour size according to the TNM classification, a degree of tumour differentiation, aging the patient and calculating a discriminant functions from the equations: Y1=-138.748+X1*15.963+X2*(-4.803)+X3*0.018+X4*2.319+X5*1.188 Y2=- 159.5454-X1*17.918+X2*(-4.266)+X3*0.028+X4*2.427+X5*1.242, wherein X1 is the primary tumour size according to the TNM classification, X2 is the degree of tumour differentiation, X3 is blood serum TIMP-1, ng/ml, X4 is a patient's age, years old; X5 is blood serum TIMP-2, ng/ml. If Y1>Y2, a high probability of the favourable outcome of the chemoradiation therapy is predicted. If Y1<Y2, a probability of no effect of the chemoradiation therapy is predicted.
EFFECT: more accurate, informative and effective treatment of the patients suffering malignant new growths of the head and neck.
2 ex
The invention relates to medicine, particularly to the Oncology and concerns to forecast the effectiveness of chemoradiation therapy () squamous carcinoma of head and neck.
There is a method of individual forecasting of treatment outcomes for patients with locally advanced common malignant tumors of oropharyngeal zone using the definition prior to treatment in the blood plasma of the patient of malonic dialdehyde (MDA): when set to MDA up to 5 units of optical density predict a favorable treatment outcome, at MDA from 5 to 8 units of optical density predict a satisfactory result of the treatment, and at MDA above 8 units of optical density predict an unfavorable outcome treatment [4].
Disadvantages of this method are:
- way in respect of the methods of treatment used for the treatment of malignant tumors of oropharyngeal zone that does not allow to assess the tactics of treatment of patients with the above localization of the tumor process.
The new technical task - increasing the accuracy and informative way.
To solve the problem in the way of predicting the effectiveness of chemoradiation therapy() accurate carcinoma of head and neck, including study of the level of TIMP-1 and TIMP-2 in the blood serum, further define the size primary tumor according to the international TNM classification, degree of differentiation of the tumor, age of the patient and expect to discriminate functions from the equations:
Y1=-138,748+X1*15,963+X2*(-4,803)+X3*0,018+X4*2,319+X5*1,188
Y2=-159,545+X1*17,918+X2*(-4,266)+X3*0,028+X4*2,427+X5*1,242,
whereX1 - the size of the primary tumor according to the international classification TNM
X2 - the degree of tumor differentiation
X3 - serum level of TIMP-1 ng/ml
X4 - age of the patient, years;
X5 - serum level of TIMP-2 ng/ml
when Y1>Y2, we predict a high probability of a good outcome , Y1<Y2 forecast the probability of absence of the effect
New in the way of the forecast is used to assess the effectiveness of mathematical model, including the most informative indicators such as the level of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in the blood serum before treatment; size of the primary tumor (T-criterion of the TNM classification of malignant tumours); the degree of differentiation of the tumor and the age of the patient.
This approach to forecasting the efficiency of patients with malignant neoplasms of the head and neck is due to a number of premises:
- production of tumor number of metalloproteinases is connected with the formation mechanisms of radioresistance tumor tissue of [1, 3];
- high level of expression of TIMP-1 near tumors was associated with a poor response to chemotherapy [2].
The method is as follows. Spend study of blood serum of patients taken 1-2 days before the radiotherapy. Serum taken in a standard way, stored at -20 degrees, not more than 10 months. Serum samples defrost not more than 1 times for a study on the level of markers. Study of the level of TIMP-1 and TIMP-2 in the blood serum is carried out using sets for enzyme-linked immunosorbent assay for ELISA analyzer. determine the size of the primary tumor, according to the international TNM classification, degree of differentiation of the tumor, age of patient and expect to discriminate functions from the equations:
Y1=-138,748+X1*15,963+X2*(-4,803)+X3*0,018+X4*2,319+X5*1,188
Y2=-159,545+X1*17,918+X2*(-4,266)+X3*0,028+X4*2,427+X5*1,242,
whereX1 - the size of the primary tumor, according to the international TNM classification
X2 - the degree of tumor differentiation
X3 - serum level of TIMP-1 ng/ml
X4 - age of the patient, years;
X5 - serum level of TIMP-2 ng/ml
when Y1>Y2, we predict a high probability of a good outcome , Y1<Y2 predict the probability of absence of the effect
The proposed method is based on the results of the analysis of clinical studies.
In the studied group consisted of 31 patients aged from 35 to 68 years (the average age was 53,5±1.3 years) with T2-4N0-2M0-stage disease who were treated in the Department of head and neck Oncology research Institute RAMS Siberian branch of confirmed malignant tumors of the larynx, pharynx and oral cavity bottom: morphologically all patients registered squamous cell cancer of various degree of differentiation. All patients received as an independent method of treatment. was performed using the 2 schemes: the first scheme (21 patients ) included 2 courses of chemotherapy (XT) on the scheme paclitaxel 175 mg/m2/ carboplatin - AUC-6, at intervals of 3-4 weeks. Then patients were LT. According to the second scheme (10 patients ) patients were LTL in standard mode in combination with 2 courses XT according to the scheme: paclitaxel 175 mg/m2/ carboplatin - AUC-6, interval between courses of 4 weeks. Results were evaluated by standard techniques and were defined as the full effect, a partial effect, stabilization or progression of cancer. Given that took part in an experiment patients treated on two protocols, the work was analyzed between background concentrations of inhibitors in the serum and treatment methods, as well as analyzed the effectiveness of the method of treatment, no significant differences in the compared groups were received, resulted in the further work to unite the patients receiving different ways in one study group.
During observation of the studied a group of patients the full effect from (regression of the tumor 100%) was registered in 8 patients, in 12 cases there was observed a partial regression of the tumor, the lack of effect of was observed in 11 patients with malignant tumors in the head and neck.
Held analysis, which resulted in the model presented two linear functions:
Y1=-138,748+X1*15,963+X2*(-4,803)+X3*0,018+X4*2,319+X5*1,188
Y2=-159,545+X1*17,918+X2*(-4,266)+X3*0,028+X4*2,427+X5*1,242, where X1 is the size of the primary tumor, according to the international TNM classification; X2 is the degree of tumor differentiation; X3 - serum level of TIMP-1 ng/ml; X4 - age of the patient, years; X5 - serum level of TIMP-2 ng/ml.
The sensitivity and specificity of the received model was 85% and 63%, diagnostic accuracy - 77%. When Y1>Y2 noted the presence of a high probability of a good effect , Y1<Y2 noted the presence of high-risk lack of effect .
Clinical examples:
Example 1. Patient N., 60 years old, was admitted to the Department HEAD of the Institute of Oncology in March 2006 with complaints about a hoarse, and sore throat. Considers himself to be ill during the year, the diagnosis is verified in the Bureau. Diagnosis: Cancer of the larynx T3N0M0. Histology: a highly differentiated squamous squamous cell carcinoma. Before treatment the patient took the blood to determine the level of TIMP-1 and TIMP-2 for forecasting chemoradiation treatment. Taking into account these indicators (TIMP-1=188,50 ng/ml (X3) and TIMP-2=88,70 ng/ml (X5), as well as the size of the primary tumor (X1=3), the degree of tumor differentiation (high) (x2=2) and age (60 years) (X4=60)were calculated discriminate functions:
Y1=-138,748+3*15,963+2*(-4,803)+188,5*0,018+60*2,319+88,695*1,188=122,0996
Y2=-159,545+3*17,918+2*(-4,266)+188,5*0,028+60*2,427+88,695*1,242=119,4554
As Y1>Y2, this patient is classified in the 1st group (with the alleged good effect chemoradiation treatment). Focusing on favorable prognosis patient was treatment as previously described. At a dose of 40 Gy efficiency of treatment was estimated as full regression. Radiation therapy is continued for up to SOD 66 . The patient was discharged in satisfactory condition is observed at the present, the total period of dynamic observation was 25 months.
Example 2. The patient,, 65 years old, was admitted to the Department HEAD in March 2008, complaining of ulcerative education on the lateral surface of the tongue. Ill since the summer of 2007, Diagnosis: Cancer language T2NOMO. Histology: squamous cell carcinoma, with a low degree of differentiation. Before treatment the patient took the blood to determine the level of TIMP-1 and TIMP-2 for forecasting chemoradiation treatment. Taking into account these indicators (TIMP-1=212,28 ng/ml (X3) and TIMP-2=106,84 ng/ml (X5), as well as the size of the primary tumor (X1=2), the degree of tumor differentiation (low) (x2=4) and age (65 years) (X4=65)were calculated discriminate functions:
Y1=-138,748+2*15,963+4*(-4,803)+212,28*0,018+65*2,319++106,84*1,188=155,448
Y2=-159,545+2*17,918+4*(-4,266)+212,28*0,028+65*2,427+106,84*1,242=155,6211
As Y1<Y2, this patient is classified in the 2nd group with the alleged bad effect chemoradiation treatment. Despite the poor prognosis in accordance with the Protocol to the patient held the instructions above. At a dose of 40 . estimated effect of the stabilization process. The effectiveness of treatment is regarded as a «bad effect». The second stage of the patient performed surgical intervention. The patient was released in satisfactory condition with a recommendation to be observed at the place of residence.
A method for predicting the effectiveness of chemoradiation therapy () squamous carcinoma of head and neck, including study of the level of TIMP-1 and TIMP-2 in the blood serum, wherein the further define the size of the primary tumor, according to the international TNM classification, degree of differentiation of the tumor, age of patient and expect to discriminate functions from the equations: Y1=-138,748+X1·15,963+X2·(-4,803)+X3·0,018+X4·2,319+X5·1,188 Y2=-159,545+X1·17,918+x2·(-4,266)+X3·0,028+X4·2,427+X5·1,242, where X1 is the size of the primary tumor according to international TNM classification; x2 is the degree of tumor differentiation; X3 - serum level of TIMP-1 ng/ml; X4 - age of the patient, years; X5 - serum level of TIMP-2 ng/ml; the Y1>Y2 predict a high probability of a good outcome , Y1<Y2 predict the probability of absence of the effect .